



Symbio Pharmaceuticals Limited

San-Ei Building, 5-23-7 Shimbashi, Minato-ku, Tokyo 105-0004, Japan
Tel: +81-3-5472-1125 Fax: +81-3-5472-3054 <http://www.symbiosis.co.jp/>

January 8, 2009

Symbio Pharmaceuticals Limited

Fuminori Yoshida

Representative Director, President and Chief Executive Officer

Bendamustine Product Registration Dossiers Submitted in Singapore

Symbio Pharmaceuticals Limited completed product registration filing for bendamustine HCl with the Singapore Health Authority (HSA) on December 24th, 2008.

Product registration dossiers for both presentations (25mg and 100mg vial) for bendamustine HCl were submitted under the trademark BENDA (trademark registration underway in Singapore). The HSA will complete their review of the dossiers over a period of 25 working days.

Bendamustine is indicated as a single agent (Ribomustin[®]) to be used as a monotherapy or in combination with other anticancer agents for NHL, MM, and CLL in Germany. Cephalon, Inc. received US FDA Approval for TREANDA[®] to treat Patients with CLL, and relapsed indolent NHL in March and October of 2008, respectively. Bendamustine is now under review by EMEA for NHL, MM and CLL in 13 EU countries, with granting of market authorizations expected in 2009.

Symbio Pharmaceuticals Ltd. holds exclusive rights from Astellas Deutschland GmbH to develop and market bendamustine HCl in Japan, China (HK), Taiwan, Korea and Singapore. Symbio and Eisai Co., Ltd. executed a license agreement for the co-development and commercialization of SyB L-0501 in Japan in August 2008. The Phase II clinical trial for the treatment of patients with relapsed indolent NHL, and Phase I trial for the treatment of patients with relapsed aggressive NHL in combination with Rituximab, are now being conducted in Japan.

[Company Profile]

Symbio Pharmaceuticals Ltd. was established in March 2005 by Fuminori Yoshida, who previously served as both Corporate VP of Amgen Ltd. and President of Amgen Japan (currently Takeda Bio Development Center Limited). The company's underlying corporate philosophy is "delivering hope to patients in need," and the company aims to address unmet medical needs of patients in Japan and other Asia Pacific regions by cultivating a mutually beneficial or symbiotic relationship among physicians, scientists, investors, government, and patients in the healthcare industry.

[Contact]

SymBio Pharmaceuticals Limited.

Osamu Ogawa,

Board Director, Senior Corporate Officer,
Senior Director, Research & Development

Tel: +081(0)3 5472 1127

e-mail: Please send your inquiry through “INQUIRY” in our homepage

URL: <http://www.symbiosis.co.jp>